{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Challenges
Regeneron Pharmaceuticals, Inc. has recently revised its evaluation amid changing market conditions. The stock is currently priced at $585.48, with a notable 52-week range. Technical indicators show mixed trends, and the company has faced significant challenges, underperforming compared to the S&P 500 over the past year.
Is Regeneron Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Regeneron Pharmaceuticals has a neutral technical outlook with mixed indicators, showing a shift from mildly bearish to sideways, while significantly underperforming the S&P 500 with year-to-date and one-year returns of -15.77% and -40.86%, respectively.
Is Regeneron Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Regeneron Pharmaceuticals shows a neutral technical trend with mixed signals, underperforming the S&P 500 significantly year-to-date and over the past year.
Regeneron Pharmaceuticals Hits Day Low Amid Price Pressure, Closing at $549.40
Regeneron Pharmaceuticals, Inc. faced a significant decline in stock value, contrasting with the broader market's performance. Over the past year, the company has experienced a substantial decrease, while maintaining strong management efficiency and healthy long-term growth in net sales, reflecting its position in the pharmaceuticals and biotechnology sector.
Regeneron Pharmaceuticals Hits Day Low Amid Price Pressure at $565.53
Regeneron Pharmaceuticals, Inc. faced a significant stock decline today, reaching an intraday low. Despite this, the company holds a strong market position with a substantial market capitalization and efficient management, evidenced by a notable return on equity. Long-term growth remains positive, supported by healthy net sales increases.
Is Regeneron Pharmaceuticals, Inc. technically bullish or bearish?
As of August 25, 2025, Regeneron Pharmaceuticals shows a mildly bearish trend with mixed technical indicators and significant underperformance, returning -47.43% over the past year compared to the S&P 500's 17.14%.
Is Regeneron Pharmaceuticals, Inc. overvalued or undervalued?
As of August 1, 2025, Regeneron Pharmaceuticals is considered fairly valued with a P/E ratio of 16, lower than some peers like Eli Lilly and Johnson & Johnson, but has underperformed the S&P 500 with a return of -47.43% over the past year.
Is Regeneron Pharmaceuticals, Inc. technically bullish or bearish?
As of May 30, 2025, Regeneron Pharmaceuticals, Inc. is in a bearish trend, supported by bearish daily moving averages, monthly MACD, and KST indicators, despite a mildly bullish weekly MACD signal.
Is Regeneron Pharmaceuticals, Inc. overvalued or undervalued?
As of April 29, 2025, Regeneron Pharmaceuticals is considered very attractive and undervalued, with a P/E ratio of 16, an EV to EBITDA of 13.64, and a ROCE of 17.20%, significantly lower than peers like Eli Lilly and Johnson & Johnson, despite a one-year stock performance of -51.39% compared to the S&P 500's 10.26%.
Who are in the management team of Regeneron Pharmaceuticals, Inc.?
As of March 2022, the management team of Regeneron Pharmaceuticals includes Dr. P. Roy Vagelos (Chairman), Dr. Leonard Schleifer (CEO), and Dr. George Yancopoulos (CSO), along with several independent directors such as Dr. Bonnie Bassler and Dr. Michael Brown.
What does Regeneron Pharmaceuticals, Inc. do?
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing medicines for serious medical conditions. As of March 2025, it reported net sales of $3.03 billion and a market cap of approximately $69.29 billion.
How big is Regeneron Pharmaceuticals, Inc.?
As of Jun 18, Regeneron Pharmaceuticals, Inc. has a market capitalization of $69.29 billion, with net sales of $14.09 billion and a net profit of $4.50 billion over the last four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
